Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer

PURPOSE: This study aimed to analyze changes in the plasma concentration of EGFR-mutated circulating tumor DNA (ctDNA) occurring immediately after the start of therapy with EGFR tyrosine kinase inhibitors (TKIs). METHODS: Serial plasma samples were collected from 30 patients with EGFR-driven non-sma...

Descripción completa

Detalles Bibliográficos
Autores principales: Moiseyenko, Fedor V., Kuligina, Ekaterina S., Zhabina, Albina S., Belukhin, Sergey A., Laidus, Tatiana A., Martianov, Aleksandr S., Zagorodnev, Kirill A., Sokolova, Tatyana N., Chuinyshena, Svetlana A., Kholmatov, Maxim M., Artemieva, Elizaveta V., Stepanova, Ekaterina O., Shuginova, Tatiana N., Volkov, Nikita M., Yanus, Grigoriy A., Imyanitov, Evgeny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853017/
https://www.ncbi.nlm.nih.gov/pubmed/35171360
http://dx.doi.org/10.1007/s10147-022-02128-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853017/
https://www.ncbi.nlm.nih.gov/pubmed/35171360
http://dx.doi.org/10.1007/s10147-022-02128-6

Ejemplares similares